Case report: Stereotactic MR-guided adaptive radiotherapy for inoperable urothelial carcinoma at the renal pelvis
Issued Date
2023-01-01
Resource Type
eISSN
2234943X
Scopus ID
2-s2.0-85182683396
Journal Title
Frontiers in Oncology
Volume
13
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Oncology Vol.13 (2023)
Suggested Citation
Thaweerat W., Dankulchai P. Case report: Stereotactic MR-guided adaptive radiotherapy for inoperable urothelial carcinoma at the renal pelvis. Frontiers in Oncology Vol.13 (2023). doi:10.3389/fonc.2023.1284417 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/95890
Title
Case report: Stereotactic MR-guided adaptive radiotherapy for inoperable urothelial carcinoma at the renal pelvis
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
We report the case of an 87-year-old woman with upper tract urothelial carcinoma at the left renal pelvis. She received stereotactic body radiotherapy of 35 Gy in five fractions for palliative treatment of hematuria that was delivered by a 1.5-T magnetic resonance (MR) imaging-guided linear accelerator. Her symptom was relieved after treatment, and posttreatment imaging revealed a complete response of the primary tumor. Thus, this case showed that stereotactic MR-guided radiotherapy could be an appealing option for inoperable patients although radiotherapy is infrequently mentioned in the current treatment guideline of upper tract urothelial carcinoma. Daily adaptive planning from MR images obtained before treatment could improve the target dose and minimize the organ at risk dose. This may lead to a decrease in radiation adverse effects including worsening renal function due to the renal pelvis tumor’s proximity to the kidney.